Comparision of Retinal Surgery by Three-dimensional Heads-up Display to the Standard Operating Microscope

NCT ID: NCT03075852

Last Updated: 2018-08-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-05-26

Study Completion Date

2018-08-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, cross-sectional, observational study investigating a three dimensional heads up display for retinal surgery and comparing its outcomes and ease of use with the standard operative microscope.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prospective, cross-sectional, observational study. Patient are undergoing vitreoretinal surgery for a variety of indications including, but not limited to, epiretinal membrane (ERM), macular hole, vitreous opacities, vitreous hemorrhage, aphakia, dislocated or displaced intraocular or crystalline lens, rhegmatogenous retinal detachment, and tractional retinal detachment. In this prospective, single-center, unmasked cross-sectional, observational case series, at minimum of 100 consecutive eyes will undergo 23-, 25-, or 27-gauge 3-port pars plana vitrectomy (PPV) with the Constellation Vision System (Alcon Laboratories, Hünenberg, Switzerland) using either the NGENUITY 3D HUD surgery platform or standard operating microscope (OPMI Lumera 700 surgical microscope with ReSight (Carl Zeiss AG, Gena, Germany), with 1:1 randomization. Surgical gauge will be dictated by operating surgeon preference. Informed consent will be obtained from all patients enrolled in accordance with the Declaration of Helsinki and all applicable HIPPA regulations. All surgeries will be digitally recorded (as is routinely done for educational purposes) and video data will be stored on password-protected, encrypted external hard-disk drives. These drives will be stored in a secure, locked cabinet in the Research Department of the Retina Service when not in use. All surgeries will be performed by 2 surgeons (AH and JH). Those randomized to 3D HUD surgery will undergo PPV with a 3D high dynamic range camera (ICM5), specialized image processing software (Version 9.5.4; TrueWare, Santa Barbara, CA), and a 46" high-definition (1980x1024 pixel) liquid crystal display (GD-463D10, Yokohama, Japan). During surgery with the 3D HUD, the surgeon will wear passive 3-D polarized glasses and will be positioned approximately 1.5 m from the display. Iris aperture and image gain will be standardized and unchanged for all cases performed with the 3D HUD. Enrolled patients will be monitored at post-operative day 1, week 1, month 1, and month 3 to measure visual acuity, undergo optical coherence tomography (OCT) if clinically indicated, and further examination to document anterior segment and dilated funduscopic examination findings. Patients undergoing epiretinal membrane (ERM) and internal limiting membrane (ILM) removal for either macular pucker or macular hole repair will be subjected to a disease-specific surgical protocol to examine potential differences in macular surgery between 3D HUD and traditional microscope visualization. These patients will undergo 25-gauge 3-port PPV with 1:1 randomization to either visualization with the 3D HUD or standard operating microscope. Indocyanine green (ICG) vital dye (\*\*% solution) will be injected in 0.1 cc aliquots to stain the ILM with the infusion cannula clamped and 60 seconds allowed for the dye to stain the ILM. Endoillumination levels will initially be set to 1% and will be increased by 1% intervals until the operating surgeon notes enough illumination to proceed with ERM/ILM peeling. ILM peeling will be performed to the boundaries of the retinal vascular arcades and the duration of membrane peeling will be documented. If the operating surgeon requests increased endoilluminaton power during membrane peeling, the increased value will be recorded. The number of macular hemorrhages and contusions induced by direct forcep trauma as well as iatrogenic retinal breaks sustained during membrane peeling will also be recorded. Data Collection Demographic data, diagnosis, clinical presentation, and history will be recorded for each patient on initial examination as is done in the course of routine care. Data elements will include age, race, date of birth, date of evaluation, medical record number, chief complaint, past ocular history, past medical history, visual acuity, anterior segment exam findings (i.e. ocular surface disease, lens status, etc.), funduscopic exams, preoperative imaging and testing (OCT, FAF, Fundus Photography). Intraoperative endoillumination levels will be recorded. Recorded surgical video files and follow-up status will be compiled for each patient and various metrics will be recorded including total operative time, time of ILM/ERM peeling, number of ICG aliquots required to visualize the ILM, and intraoperative complications. Baseline and follow up data will also include visual acuity, anterior segment and funduscopic examination, and OCT data if applicable. Other data collected will include subjective physician surveys on the use of the two visualization systems, including quality of visualization on a 10-point scale, perceived subjective difficulties with vitreoretinal visualization, and overall ergonomic comfort on a 10-point scale. Human Subjects and Informed Consent The tenets of the Declaration of Helsinki will be followed and written informed consent obtained at the time of patient enrollment. Patients will also be provided with a lay explanation of the study goals and protocol. The decision to enroll in the study is entirely elective and patients will not be reimbursed for their participation. The PHI and privacy of subjects will be maintained by strict adherence to HIPPA and Wills Eye Institute policies. The aforementioned data will be stored prospectively as patients are enrolled. All data upon collection will be coded and de-identified. Codes will be created for each consecutive patient via a random number generator. All data will be stored on a computer stored and ecrypted hard drives within an ecrypted password protected Microsoft Excel file only accessible to members of the study team. De-identified data will be linked to medical record numbers and date of birth. No other patient identifiers will be recorded

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Comparison of 3D Visualization and Microscope for VR Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

3D VRS Patients

Those who undergo surgery with NGENUITY (3D VRS-Vitreoretinal surgery)

Heads- Up Display Surgery

Intervention Type DEVICE

Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon.

Standard operating microscope

Those who undergo surgery with the standard operating microscope

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Heads- Up Display Surgery

Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NGENUITY surgical display system

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Eligible patients are those age 18 or older undergoing vitreoretinal surgery for a variety of indications including, but not limited to, epiretinal membrane (ERM), macular hole, vitreous opacities, vitreous hemorrhage, aphakia, dislocated or displaced intraocular or crystalline lens, rhegmatogenous retinal detachment, and tractional retinal detachment

Exclusion Criteria

* Prisoners, institutionalized patients, and those who have undergone previous pars plana vitrectomy will be excluded. Patients undergoing combined, simultaneous scleral buckle placement and pars plana vitrectomy will also be excluded
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alcon Research

INDUSTRY

Sponsor Role collaborator

MidAtlantic Retina

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

MidAtlantic Retina

Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Allen C Ho, MD

Role: PRINCIPAL_INVESTIGATOR

Mid Atlantic Retina

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MidAtlantic Retina-Wills Eye Hospital

Philadelphia, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Eckardt C, Paulo EB. HEADS-UP SURGERY FOR VITREORETINAL PROCEDURES: An Experimental and Clinical Study. Retina. 2016 Jan;36(1):137-47. doi: 10.1097/IAE.0000000000000689.

Reference Type BACKGROUND
PMID: 26200516 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17-609E

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Vitrectomy Retinal Oxygenation
NCT01510691 WITHDRAWN